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Neurocognitive decline, such as, poor performance on tasks of simple attention, visuospatial ability and motor dexterity,2 has been reported previously in patients with SLE. Marked cognitive impairment was observed in some patients even After the first dose which she took in the evening she awoke the same night with "severe pain in the whole body" which she felt was distinct from her usual joint pain in that it appeared to be located in her muscles rather than her joints. She was unable to move for seven hours due to the pain and stiffness which she described as "like being held down". She felt non-specifically unwell for a further two days. Having felt that this was probably coincidental she took a further dose the following week but developed identical symptoms which again lasted two days. She has now discontinued methotrexate and not experienced any further similar symptoms. Before starting the methotrexate her plasma viscosity was 1-84 cp (NR 1-5-1-72), haemoglobin 11-1 g/dl and immediately after the adverse reaction the plasma viscosity was 1-68, haemoglobin 12-5 g/dl. No other investigations were performed since at the time the patient did not report on the adverse reaction or that she had stopped the methotrexate.
A 48 year old woman had an 18 month history of seropositive erosive rheumatoid arthritis and bronchiectasis. She had previously been treated with D-penicillamine (discontinued due to proteinuria) and sulphasalazine (discontinued due to diarrhoea). Her other medication included coproxamol, diclofenac, prednisolone 2-5 mg daily, ranitidine, bisacodyl, and salbutamol and beclomethasone inhalers. Due to persistent synovitis she was started on oral methotrexate 5 mg weekly. Three hours after the first dose at 5 pm she felt as if she had "severe flu", with widespread aching throughout her body and neck. The following day she felt unable to move due to weakness and pain. She also developed blistering of the mouth. The symptoms lasted three days and fully resolved. They recurred in indentical fashion following two further doses of the methotrexate.
Before starting the methotrexate her plasma viscosity was 1-76 cp; following the initial doses it rose to 1-83 cp. The full blood count and differential remained unchanged as did her serum biochemistry; creatinine kinase was normal at 31 IU/l . Since discontinuing the methotrexate there have been no further similar episodes.
The consistent temporal relationship to the methotrexate dose would seem to make a true association likely. We have, however, been unable to uncover any previous reports of a similar adverse event. Unfortunately, in both cases the episode was not witnessed by a physician, and neither patient was willing to undergo rechallenge with the drug under observation due to the severity of the symptoms. The rapid time course is intriguing, suggesting either an immediate hypersensitivity reaction or a pharmacological effect. The onset of action is compatible with the known rapid absorption
